Financial Daily from THE HINDU group of publications
Saturday, Nov 20, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Markets - Stock Markets


Pharma stocks move southward

Virendra Verma

Mumbai , Nov. 19

PHARMA companies' shares were not hammered as much in India as in the European market where the shares of leading pharma companies took a knock on the news of scrutiny of five drugs.

In the European market, companies such as GlaxoSmithKline and AstraZeneca fell sharply after the news of US FDA calling for a close watch of these drugs.

On the Indian bourses, the BSE Healthcare Index saw a dip of 1.37 per cent compared to over one per cent fall by the BSE Sensex.

Among the stocks that fell were GlaxoSmithKline Pharma (down 1.53 per cent at Rs 747.05 on the BSE), Aventis Pharma (down 3.25 per cent at Rs 1,064.35), Dr Reddy's Laboratories (1.33 per cent at Rs 789), Cipla (0.90 per cent at Rs 265.15) and IPCA Laboratories (0.89 per cent at Rs 754).

More Stories on : Pharmaceuticals | Stock Markets

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Infosys, Reliance, Tata, Wipro among world's most respected cos


Inflation up on costlier petro products
Bountiful reverse monsoon makes up for past deficit
Maran's 10-point action plan for BSNL, MTNL to face competition
More withdrawals from WHO list; US scrutiny — Indian pharma companies face testing times
Pharma stocks move southward
Reliance drags indices down
Textile industry gets a fillip through TUFS
Mallya to hold talks with global brewers
Madura Garments set to bring Armani to India
Notification issued on rubber exports subsidy — Sops for all grades cut by half for current fiscal



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line